Search Results - "Rebersek, Martina"

Gut microbiome and its role in colorectal cancer by Rebersek, Martina

“…Colorectal cancer (CRC) is still one of the most common types of cancer in the world, and the gut microbiome plays an important role in its development. The…”
Get full text

Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision by Rebersek, Martina

“…Background Colorectal cancer (CRC) is one of the most common types of cancer in the world. Metastatic disease is still incurable in most of these patients, but…”
Get full text

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018 by Mesti, Tanja, Rebersek, Martina, Ocvirk, Janja

“…We preformed a Phase IV non-interventional study to assess KRAS, NRAS and BRAF status in metastatic colorectal cancer (mCRC) patients suitable for 1st line…”
Get full text

Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study by Hribernik, Nezka, Strasek, Katja, Huff, Daniel T, Studen, Andrej, Zevnik, Katarina, Skalic, Katja, Jeraj, Robert, Rebersek, Martina

“…To evaluate the role of the novel quantitative imaging biomarker (QIB) SUV of F-FDG uptake extracted from early F-FDG-PET/CT scan at 4 weeks for the detection…”
Get full text

Determination of copper and other trace elements in serum samples from patients with biliary tract cancers: prospective noninterventional nonrandomized clinical study protocol by Rebersek, Martina, Hribernik, Nezka, Markovic, Katarina, Markovic, Stefan, Valentinuzzi, Katja Ursic, Cemazar, Maja, Zuliani, Tea, Milacic, Radmila, Scancar, Janez

“…Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage, when the disease is incurable. Currently used tumor biomarkers have limited diagnostic…”
Get full text

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial by Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja

“…Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There…”
Get full text

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients by Rebersek, Martina, Mesti, Tanja, Boc, Marko, Ocvirk, Janja

“…Background Histological parameters of primary tumour and nodal metastases are prognostic factors for survival of operable colorectal (CRC) patients, but not…”
Get full text

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience by Hribernik, Nezka, Boc, Marko, Ocvirk, Janja, Knez-Arbeiter, Jasna, Mesti, Tanja, Ignjatovic, Marija, Rebersek, Martina

“…Background Based on recent data from clinical trials, the immune checkpoint inhibitor pembrolizumab prolongs survival and has a good toxicity profile in…”
Get full text

Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer by Ocvirk, Janja, Reberšek, Martina, Skof, Erik, Hlebanja, Zvezdana, Boc, Marko

“…The aim of this study was to compare the efficacy and safety of the epirubicin, cisplatin, and continuous infusion of 5-fluorouracil (ECF) regimen with that of…”
Get full text

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma by Moltara, Maja Ebert, Novakovic, Srdjan, Boc, Marko, Bucic, Marina, Rebersek, Martina, Zadnik, Vesna, Ocvirk, Janja

“…Background BRAF, NRAS and c-KIT mutations are characteristics of tumour tissues that influence on treatment decisions in metastatic melanoma patients. Mutation…”
Get full text

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience by Mesti, Tanja, Ebert Moltara, Maja, Boc, Marko, Rebersek, Martina, Ocvirk, Janja

“…Background. Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that…”
Get full text

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience by Ocvirk, Janja, Moltara, Maja Ebert, Mesti, Tanja, Boc, Marko, Rebersek, Martina, Volk, Neva, Benedik, Jernej, Hlebanja, Zvezdana

“…Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries…”
Get full text

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study by Hribernik, Nežka, Huff, Daniel T, Studen, Andrej, Zevnik, Katarina, Klaneček, Žan, Emamekhoo, Hamid, Škalic, Katja, Jeraj, Robert, Reberšek, Martina

“…Purpose To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving…”
Get full text

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1 st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wt RAS ) - a real- life data report 2013-2018 by Mesti, Tanja, Rebersek, Martina, Ocvirk, Janja

“…We preformed a Phase IV non-interventional study to assess KRAS, NRAS and BRAF status in metastatic colorectal cancer (mCRC) patients suitable for 1 line…”
Get full text

KRAS, NRAS and BRAF mutational status and first line treatment patterns in Slovenian population with metastatic colorectal carcinoma: Five year results by Mesti, Tanja, Boc, Marko, Rebersek, Martina, Hlebanja, Zvezdana, Volk, Neva, Ocvirk, Janja

“…Abstract only e15546 Background: A phase IV non-interventional study was performed from 2013 till 2018 including 650 patients with primary aim to assess KRAS,…”
Get full text

Treatment of BRAF-mutated metastatic melanoma patients with targeted therapy combinations or immunotherapy in real world setting by Ocvirk, Janja, Ignjatovic, Marija, Rebersek, Martina, Boc, Marko

“…Abstract only…”
Get full text

Recommendations from the Institute of Oncology Ljubljana for the treatment of patients with small bowell adenocarcinoma by Erik Brecelj, Vesna Zadnik, Ksenija Strojnik, Nina Boc, Gorana Gašljević, Jera Jeruc, Gašper Pilko, Martina Reberšek, Franc Anderluh

Get full text

Patients with metastatic melanoma treated with vemurafenib as monotherapy or in combination with cobimetinib by Ocvirk, Janja, Rebersek, Martina, Boc, Marko, Mesti, Tanja

“…Abstract only e21016 Background: This is a retrospective analysis of patients (pts) with metastatic melanoma (mM) designed to evaluate the efficacy and safety…”
Get full text

Treatment with vemurafenib in patients with metastatic melanoma by Ocvirk, Janja, Boc, Marko, Mesti, Tanja, Rebersek, Martina

“…Abstract only…”
Get full text

Vemurafenib in patients with metastatic malignant melanoma by Ocvirk, Janja, Mesti, Tanja, Boc, Marko, Rebersek, Martina

“…Abstract only…”
Get full text